Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.97 |
| ▸ | POLB | P06746 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12425968 | 0.98 | SMN1; SMN2 (1.00) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL29986910 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL24815673 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL12385780 | 0.81 | SMN1; SMN2 (0.66) | SMN1; SMN2POLBALDH1A1HSD17B10GAA | |
| SCHEMBL19277488 | 0.81 | POLB (0.65) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL12384423 | 0.78 | SMN1; SMN2 (0.61) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL19277458 | 0.77 | POLB (0.61) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL6032510 | 0.77 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL1493731 | 0.77 | POLB (0.60) | SMN1; SMN2POLBALDH1A1HTTRAB9A | |
| SCHEMBL1463428 | 0.75 | SMN1; SMN2 (0.58) | SMN1; SMN2POLBALDH1A1HSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364208-B2 | Oxidative coupling of aryl boron reagents with SP3-carbon nucleophiles, and ambient decarboxylative arylation of malonate half-esters via oxidative catalysis | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-07-30 | — | — | US | disclosed |
| US-20180186721-A1 | OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2018-07-05 | — | — | US | disclosed |
| US-20180186721-A1 | OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364208-B2 | Oxidative coupling of aryl boron reagents with SP3-carbon nucleophiles, and ambient decarboxylative arylation of malonate half-esters via oxidative catalysis | SOD1, AOC3, CBR3 | SMN1; SMN2 1011/4885POLB 176/4885ALDH1A1 862/4885 |
| US-20180186721-A1 | OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS | SOD1, AOC3, CBR3 | SMN1; SMN2 1011/4885POLB 176/4885ALDH1A1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.